Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Harvard Business School
Citi
AstraZeneca
Healthtrust
Covington
Federal Trade Commission
Cipla

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,056,100

« Back to Dashboard

Summary for Patent: 9,056,100
Title:Quinuclidine derivatives and medicinal compositions containing the same
Abstract: Provided is a powder inhalant comprising 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicy- clo[2.2.2]octane bromide and methods of using the same.
Inventor(s): Fernandez Forner; Maria Dolors (Barcelona, ES), Prat Quinones; Maria (Barcelona, ES), Buil Albero; Maria Antonia (Barcelona, ES)
Assignee: ALMIRALL, S.A. (Barcelona, ES)
Application Number:14/311,102
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 9,056,100

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca Pharms TUDORZA PRESSAIR aclidinium bromide POWDER, METERED;INHALATION 202450-001 Jul 23, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) OR CHRONIC BRONCHITIS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,056,100

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Spain9901580Jul 14, 1999

Non-Orange Book US Patents Family Members for Patent 9,056,100

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,129,405 Quinuclidine derivatives and medicinal compositions containing the same ➤ Sign Up
7,750,023 Quinuclidine derivatives and medicinal compositions containing the same ➤ Sign Up
7,109,210 Quinuclidine derivatives and medicinal compositions containing the same ➤ Sign Up
7,196,098 Quinuclidine derivatives and medicinal compositions containing the same ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Fuji
Cantor Fitzgerald
Healthtrust
Merck
QuintilesIMS
Covington
Argus Health
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.